Lexeo Therapeutics, Inc.: 5%+ holders

As of November 6, 2026, 12 holders' latest Schedule 13D or 13G filings report owning 5% or more of Lexeo Therapeutics, Inc. The largest reported stake is Balyasny Asset Management L.P.'s, at 9.99%. 32 filings are on record since August 7, 2025 (Schedule 13G/A, August 14, 2026).

Longitude Capital Partners IV, LLC also filed stake reports on 2 other companies ↓

Sell to companies like Lexeo Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-10-13 · Reporting person: Jpmorgan Chase & Co. · Sole voting: 4,279,401 · Shared voting: 0 · Sole dispositive: 4,573,701 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-13
• Filing 2026-08-14 · Reporting person: Balyasny Asset Management L.P. · Sole voting: 7,844,311 · Shared voting: 0 · Sole dispositive: 7,844,311 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Paradigm BioCapital Advisors LP · Sole voting: 4,175,382 · Shared voting: 0 · Sole dispositive: 4,175,382 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: OrbiMed Advisors LLC · Sole voting: 0 · Shared voting: 3,203,050 · Sole dispositive: 0 · Shared dispositive: 3,203,050 · SCHEDULE 13G, 2026-08-14
• Filing 2026-08-13 · Reporting person: Affinity Asset Advisors, LLC · Sole voting: 6,674,913 · Shared voting: 0 · Sole dispositive: 6,674,913 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-13

Lexeo Therapeutics, Inc. has 32 Schedule 13D or 13G filings on record since 2025-08-07. 12 holders' latest filing reports 5% or more of common stock ($0.0001 par value). Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Lexeo Therapeutics, Inc. and the warning signs.

See Lexeo Therapeutics, Inc.'s free Snapshot Watch Lexeo Therapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Lexeo Therapeutics, Inc. and the records around it.

Lexeo Therapeutics, Inc. elsewhere on the record

• Acquisition Sep 2026
• Who owns it

Companies that share a holder

• Longitude Capital Partners IV, LLC also filed stake reports on 2 other companies: ZENAS BIOPHARMA, INC. (Oct 2025), CG Oncology, Inc. (Sep 2025)
• Affinity Asset Advisors, LLC also filed stake reports on 13 other companies: Amanat Acquisition Corp. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Equillium Inc. (Aug 2026)
• Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies: Obsidian Therapeutics, Inc. (Oct 2026), Spyre Therapeutics, Inc. (Oct 2026), Tyra Biosciences, Inc. (Sep 2026)

Want the whole picture on Lexeo Therapeutics, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Lexeo Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Lexeo Therapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   34 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Lexeo Therapeutics, Inc. by CUSIP 52886X107 and gives its principal executive office as 345 Park Avenue South, Floor 6, New York, NY 10010 (SCHEDULE 13G, 2026-10-13).

What the percentages are based on

Each of the Reporting Persons may be deemed to be the beneficial owner of approximately 9.99% of the Shares, based on 78,521,634 Shares outstanding as of May 7, 2026, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on May 11, 2026.Balyasny Asset Management L.P., SCHEDULE 13G/A, 2026-08-14

See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 78,521,634 shares of Common Stock outstanding as of May 7, 2026, as reported by the Issuer in its Form 10-Q filed with the SEC on May 11, 2026.Paradigm BioCapital Advisors LP, SCHEDULE 13G/A, 2026-08-14

Timeline

Swipe the table sideways to see every column.

Questions about who owns Lexeo Therapeutics, Inc.

Who owns Lexeo Therapeutics, Inc.?

On this page, 12 holders' latest ownership filings report 5% or more of Lexeo Therapeutics, Inc.: Balyasny Asset Management L.P. (9.99%, Schedule 13G/A, filed 2026-08-14), Janus Henderson Group Plc (9.99%, Schedule 13G/A, filed 2025-12-08), Affinity Asset Advisors, LLC (8.4%, Schedule 13G/A, filed 2026-08-13), Suvretta Capital Management, LLC (7.7%, Schedule 13G, filed 2026-04-13) and Vestal Point Capital, LP (7.5%, Schedule 13G/A, filed 2025-11-14); 7 more are listed above.

Who are the largest shareholders of Lexeo Therapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of Lexeo Therapeutics, Inc. on this page are Balyasny Asset Management L.P. (9.99%), Janus Henderson Group Plc (9.99%) and Affinity Asset Advisors, LLC (8.4%).

When did Balyasny Asset Management L.P. buy into Lexeo Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Balyasny Asset Management L.P. on this page is the Schedule 13G, filed 2025-08-14, reporting 9.99%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.99%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 32 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Lexeo Therapeutics, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Lexeo Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Lexeo Therapeutics, Inc. is mentioned again
• Find former Lexeo Therapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes